Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
10 Results Found
AHA Statement on 340B Report From Senator Cassidy
The AHA appreciates Senator Cassidy’s leadership on 340B issues. As his report correctly observes, the 340B Program was created to help hospitals reach more eligible patients and provide more comprehensive services.
AHA Advertorial: 340B Drug Pricing Program Helps Advance Health for Patients and Communities
For 30 years, the 340B drug pricing program has helped eligible hospitals offer a wide range of important programs and services that benefit patients and advance health within their communities.
AHA, 340B Health, Arkansas Hospital Association Urge Federal Appeals Court 340B Community Pharmacies to Uphold State Law Protecting
The American Hospital Association (AHA), 340B Health, and the Arkansas Hospital Association told the U.S. Court of Appeals for the Eighth Circuit that Arkansas’s 340B Drug Pricing Nondiscrimination Act does not conflict with federal law but rather supports Congress’s goal in enacting the 340B program.
AHA Survey: Drug Companies Reduce Access to Care by Limiting 340B Community Pharmacies
The American Hospital Association (AHA) today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country.
Joint Statement From National Hospital Associations on PhRMA-Led Proposal to Restrict 340B Eligibility
Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.
AHA Statement on District Court Decision in 340B Case
For more than five years, the Department of Health and Human Services has unlawfully withheld vital funding from 340B hospitals that helps them provide a range of important benefits to their patients and communities. We are disappointed that the district court elected to extend this delay by remanding this case back to the department to determine the appropriate remedy.
Joint Statement on 340B Supreme Court Decision from AHA, AAMC, & America's Essential Hospitals
We are pleased that the U.S. Supreme Court unanimously agreed with us that the Department of Health and Human Services' outpatient payment cuts to hospitals in the 340B Drug Pricing Program were unlawful.
AHA Statement on 2023 OPPS Proposed Rule
Stacey Hughes
Executive Vice President
American Hospital Association
July 15, 2022
AHA Statement on 2023 OPPS Final Rule
While the AHA is pleased that CMS will provide hospitals and health systems with an improved update to outpatient payments next year compared to the agency’s proposal in July, the increase is still insufficient given the extraordinary cost pressures hospitals face from labor, supplies, equipment, drugs and other expenses.
AHA Statement on Court Ruling Halting 2022 340B Drug Pricing Program Cuts
The AHA appreciates Judge Contreras’ ruling that the Department of Health and Human Services must immediately stop unlawful reimbursement cuts for 2022 for hospitals participating in the 340B drug pricing program. Halting these cuts will help 340B hospitals provide comprehensive health services to their patients and communities.